Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC

Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC

The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals.

Cohance Lifesciences invests $18 million to strengthen ADC strategy

The investments will bring research, manufacturing and next-generation ADC capabilities together as Cohance expands its end-to-end CRDMO offering

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program - The Tribune

Gurugram (Haryana)/ New Delhi [India], September 3: ZoeNCure Therapeutics Pvt. Ltd., an oncology biotechnology company focused on developing high-potency targeted cancer therapies, today announced the successful closing of an INR 20 Crore (approx. $2.4 Million USD) Seed financing round. The investment was led by the HNI (High-Net-Worth Individual) Tyagi Family based out of Gurugram, India, led by Mr. Shyambir Tyagi and Manoj Tyagi, alongside par…

ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer

BusinessWire India New Delhi [India], September 3: ZoeNCure Therapeutics Pvt. Ltd., an oncology biotechnology company based in New Delhi, today announced a strategic licensing agreement with San Diego-based Styx Biotechnologies, Inc. Under the terms of the agreement, ZoeNCure has secured rights to license proprietary antibody technology and candidates to develop and commercialize next-generation antibody-drug conjugates […]

Cohance Lifesciences advances its ADC strategy

Cohance Lifesciences announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 […]

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

Business Wire India ZoeNCure Therapeutics Pvt. Ltd., an oncology biotechnology company focused on developing high-potency targeted cancer therapies, today announced the successful closing of an INR 20 Crore (approx. $2.4 Million USD) Seed financing round. The investment was led by the HNI (High-Net-Worth Individual) Tyagi Family based out of Gurugram, India, led by Mr. Shyambir Tyagi and […]